cancer treatments

Patient experience with immunotherapy: 4 things health execs need to knowCAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.
Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
First gene therapy for cancer approved: What health execs should knowThe first therapy based on gene transfer has been approved by the FDA. What’s next for healthcare executives?
Insurers benefit from getting on board with Cancer MoonShot 2020Drugs will be provided to health plan members on clinical trials free of charge.
New cancer care approach: Highmark’s cancer collaborativeCancer care has made great strides in the U.S., but effective care is still too expensive and inaccessible for many Americans. Now, payers and providers at Highmark, Allegheny Health Network and Johns Hopkins are launching a new model that could change cancer collaboration.
Top challenges in measuring cancer care qualityDetermining what to measure, and how best to measure it, can be surprisingly complex—and appropriate metrics can vary between cancer types and patient populations.
First chemo drug to show survival benefit for liposarcoma passesFDA recently approved (Halaven, Eisai), the first chemotherapy drug to demonstrate survival benefit for liposarcoma that cannot be removed by surgery or is advanced.
Sonidegib offers new option for basal cell cancerA newly approved medication called sonidegib (Odomzo) gives physicians a second option in a class of medications designed to treat a small number of patients who suffer from locally advanced basal cell carcinoma and meet other criteria. Learn more
Midostaurin extends survival among some AML patients: StudyAML’s genetic complexity raises concerns about long-term prospects of single mutation-targeting agents
Are CAD mammograms a waste of money?
Are CAD mammograms a waste of money?A study examines whether computer-assisted detection on mammography provides sufficient benefit for the cost. Plus: Do first-time pregnancy cesarean deliveries increase the preterm birth in subsequent pregnancies. And, is conventional wisdom surrounding pregnancy and cancer accurate?